Glaukos Co. (NYSE:GKOS - Get Free Report) Director Gilbert H. Kliman sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now owns 32,336 shares of the company's stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

NYSE:GKOS traded down $2.52 during midday trading on Monday, reaching $148.36. The stock had a trading volume of 446,681 shares, compared to its average volume of 576,100. The stock has a market capitalization of $8.18 billion, a P/E ratio of -49.13 and a beta of 1.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 1-year low of $74.75 and a 1-year high of $151.92. The firm's fifty day simple moving average is $138.42 and its 200-day simple moving average is $128.46.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same period in the previous year, the company posted ($0.50) earnings per share. The firm's revenue for the quarter was up 23.9% on a year-over-year basis. On average, equities research analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of GKOS. Raymond James & Associates raised its stake in Glaukos by 23.2% during the 2nd quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier's stock valued at $1,541,000 after purchasing an additional 2,452 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Glaukos by 6.8% in the second quarter. Bank of New York Mellon Corp now owns 413,680 shares of the medical instruments supplier's stock valued at $48,959,000 after buying an additional 26,510 shares during the period. Allspring Global Investments Holdings LLC grew its position in Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier's stock worth $48,805,000 after buying an additional 246,322 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Glaukos by 11.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,725 shares of the medical instruments supplier's stock valued at $1,269,000 after acquiring an additional 1,104 shares during the period. Finally, Commonwealth Equity Services LLC raised its holdings in Glaukos by 20.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 5,620 shares of the medical instruments supplier's stock valued at $665,000 after acquiring an additional 963 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

GKOS has been the subject of a number of research reports. Morgan Stanley lowered shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 target price for the company. in a research note on Monday, December 2nd. Stifel Nicolaus boosted their target price on Glaukos from $145.00 to $153.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. Stephens raised Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. UBS Group initiated coverage on Glaukos in a research note on Friday, December 6th. They issued a "buy" rating and a $182.00 price target for the company. Finally, Truist Financial raised their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Glaukos currently has an average rating of "Moderate Buy" and a consensus price target of $145.92.

Get Our Latest Research Report on Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.